Journal: Vaccines

Article Title: An Adjuvanted Vaccine-Induced Pathogenesis Following Influenza Virus Infection

doi: 10.3390/vaccines12060569

Figure Lengend Snippet: Protection against the influenza A virus induced by distinct vaccine formulations in Freund’s adjuvants. BALB/c mice were immunized s.c. with ○: IFA as a control group (a), □: CFA plus an antigen (b), ▽: IFA plus an antigen (c), ▲: IFA plus an antigen formulated with α-GC (d), and ◇: IFA plus an antigen formulated with C34 (e). Following the final immunization, immunized mice were challenged with A/California/07/2009 (H1N1 virus). Mortality was recorded daily subsequent to a lethal challenge of influenza A virus.

Article Snippet: A serial dilution of a recombinant HA or an inactivated influenza antigen was spotted on a microarray slide to detect the level of the influenza A virus, H1N1-specific antibody response (AD3200, BioDot Inc., Irvine, CA, USA).

Techniques: Virus, Control

Journal: Vaccines

Article Title: An Adjuvanted Vaccine-Induced Pathogenesis Following Influenza Virus Infection

doi: 10.3390/vaccines12060569

Figure Lengend Snippet: Protection against mortality and morbidity induced by distinct vaccine formulations in an aluminum hydroxide adjuvant following infection with the A/California/07/2009 (H1N1) virus. BALB/c mice were immunized s.c. with ●: PBS as a control group (a), △: IFA (b), ▼: AH (c), □: IFA plus antigens (d), ◇: AH plus antigens (e), ○: AH plus antigens formulated with α-GC (f), and ▽: AH plus antigens formulated with C34 (g). Immunized mice were challenged with an A/California/07/2009 (H1N1) virus following the final immunization at a 3-week interval. Mortality ( A ) and morbidity ( B , C ) were observed and recorded daily after a lethal challenge of the A/California/07/2009 virus. ( C ) was the magnified version of ( B ) from day 2 to 9. A similar result was reproducible in another independent experiment (ANOVA analysis from day 4 to 9, p < 0.05). Three virus-infected mice in group a and b had weight loss beyond 20% on day 15. They were terminated with humane euthanasia on day 16 with concern to other pain indices. □: The ruffled fur and slower locomotion were observable pathogenic signs in the group immunized with an IFA plus antigens (d).

Article Snippet: A serial dilution of a recombinant HA or an inactivated influenza antigen was spotted on a microarray slide to detect the level of the influenza A virus, H1N1-specific antibody response (AD3200, BioDot Inc., Irvine, CA, USA).

Techniques: Adjuvant, Infection, Virus, Control

Journal: Journal of Virological Methods

Article Title: Multiplexed, microscale, microarray-based serological assay for antibodies against all human-relevant coronaviruses

doi: 10.1016/j.jviromet.2021.114111

Figure Lengend Snippet: (a) Schematic illustration of VaxArray CoV SeroAssay slide with 16 identical microarrays labeled A1 through H2, (b) Layout of an individual microarray including 9 unique capture antigens labeled nCoV(i) through NL63, each printed as 9 replicate spots. Fiducial markers are shown as grey spots in rows above and below capture antigens. (c) Schematic of the immunoassay principle in which capture antigen binds target antibodies from serum, and target antibodies are labeled using a species-specific IgG secondary antibody label that contains a fluorescent tag. S refers to full-length spike, and S1, S2, and RBD refer to corresponding portions of spike as called out in .

Article Snippet: The VaxArray platform (InDevR, Inc., Boulder, CO) is a microscale, multiplexed, microarray-based immunoassay platform that has been well-validated for use in influenza vaccine antigen characterization ( ; ), and has been adapted for serological analysis of coronaviruses with the recent availability of the Coronavirus (CoV) SeroAssay.

Techniques: Labeling, Microarray

Journal: Journal of Virological Methods

Article Title: Multiplexed, microscale, microarray-based serological assay for antibodies against all human-relevant coronaviruses

doi: 10.1016/j.jviromet.2021.114111

Figure Lengend Snippet: (a) Schematic illustration of microarray layout, and representative fluorescence images of the VaxArray CoV SeroAssay microarray in (b) through (l). Images (b) through (h) show the variety of responses to the endemic human CoV capture antigens for specimens from pediatric donors (ages noted for each image), and images (i) through (l) show responses from 4 unique COVID-19 positive donors of unknown age.

Article Snippet: The VaxArray platform (InDevR, Inc., Boulder, CO) is a microscale, multiplexed, microarray-based immunoassay platform that has been well-validated for use in influenza vaccine antigen characterization ( ; ), and has been adapted for serological analysis of coronaviruses with the recent availability of the Coronavirus (CoV) SeroAssay.

Techniques: Microarray, Fluorescence

Journal: Journal of Virological Methods

Article Title: Multiplexed, microscale, microarray-based serological assay for antibodies against all human-relevant coronaviruses

doi: 10.1016/j.jviromet.2021.114111

Figure Lengend Snippet: Positive and Negative Percent Agreement between VaxArray CoV SeroAssay for the detection of SARS-CoV-2 compared to a Mixed Reference Method. a

Article Snippet: The VaxArray platform (InDevR, Inc., Boulder, CO) is a microscale, multiplexed, microarray-based immunoassay platform that has been well-validated for use in influenza vaccine antigen characterization ( ; ), and has been adapted for serological analysis of coronaviruses with the recent availability of the Coronavirus (CoV) SeroAssay.

Techniques:

Journal: medRxiv

Article Title: Multiplexed, Microscale, Microarray-based Serological Assay for Antibodies Against All Human-Relevant Coronaviruses

doi: 10.1101/2020.09.03.20179598

Figure Lengend Snippet: (a) Schematic illustration of VaxArray CoV SeroAssay slide with 16 identical microarrays labeled A1 through H2, (b) Layout of an individual microarray including 9 unique capture antigens labeled nCoV(i) through NL63, each printed as 9 replicate spots. Fiducial markers are shown as grey spots in rows above and below capture antigens. (c) Schematic of the immunoassay principle in which capture antigen binds target antibodies from serum, and target antibodies are labeled using a species-specific IgG secondary antibody label that contains a fluorescent tag.

Article Snippet: The VaxArray platform (InDevR, Inc., Boulder, CO) is a microscale, multiplexed, microarray-based immunoassay platform that has been well-validated for use in influenza vaccine antigen characterization, , and has been adapted for serological analysis of coronaviruses with the recent availability of the Coronavirus (CoV) SeroAssay.

Techniques: Labeling, Microarray

Journal: medRxiv

Article Title: Multiplexed, Microscale, Microarray-based Serological Assay for Antibodies Against All Human-Relevant Coronaviruses

doi: 10.1101/2020.09.03.20179598

Figure Lengend Snippet: Fluorescence microarray images illustrating binding of monoclonal antibodies to the CoV SeroAssay. (a) CR3022 SARS-CoV-1 antibody from Creative Biolabs binding to the nCoV(ii) and SARS antigens, (b) 40021-MM07 HKU1 antibody from Sino Biological binding to HKU1 antigen, (c) 40069-MM23 MERS antibody from Sino Biological binding to the MERS antigen, and (d) GTX632604 SARS-CoV-2 antibody from Genetex binding to the nCoV(i) and nCoV(iii) antigens.

Article Snippet: The VaxArray platform (InDevR, Inc., Boulder, CO) is a microscale, multiplexed, microarray-based immunoassay platform that has been well-validated for use in influenza vaccine antigen characterization, , and has been adapted for serological analysis of coronaviruses with the recent availability of the Coronavirus (CoV) SeroAssay.

Techniques: Fluorescence, Microarray, Binding Assay

Journal: medRxiv

Article Title: Multiplexed, Microscale, Microarray-based Serological Assay for Antibodies Against All Human-Relevant Coronaviruses

doi: 10.1101/2020.09.03.20179598

Figure Lengend Snippet: (a) Schematic illustration of microarray layout, and representative fluorescence images of the VaxArray CoV SeroAssay microarray in (b) through (l). Images (b) through (h) show the variety of responses to the endemic human CoV capture antigens for specimens from pediatric donors (ages noted for each image), and images (i) through (l) show responses from 4 unique COVID-19 positive donors of unknown age.

Article Snippet: The VaxArray platform (InDevR, Inc., Boulder, CO) is a microscale, multiplexed, microarray-based immunoassay platform that has been well-validated for use in influenza vaccine antigen characterization, , and has been adapted for serological analysis of coronaviruses with the recent availability of the Coronavirus (CoV) SeroAssay.

Techniques: Microarray, Fluorescence

Journal: Bioengineering

Article Title: COVID-19 Diagnostic Strategies Part II: Protein-Based Technologies

doi: 10.3390/bioengineering8050054

Figure Lengend Snippet: The developed protein microarray-based tests for COVID-19 detection.

Article Snippet: PEPperPRINT GmbH [ ] , PEPperCHIP ® Pan-Corona Spike Protein Microarray , Antibodies against S antigen , S proteins derived from seven coronaviruses translated into overlapping peptides , (No info) , (No info) , One array with 4564 peptides in duplicate , RUO , For Serum antibody fingerprint analysis, Immune monitoring and Epitope studies.

Techniques: Microarray, Peptide Microarray, Bioprocessing, Derivative Assay, High Throughput Screening Assay, Enzyme-linked Immunosorbent Assay, Western Blot, Virus, Clinical Proteomics